Omrix claims US first for fibrin sealant:
This article was originally published in Clinica
Omrix biopharmaceuticals has launched in the US what it claims to be the country's first commercially available liquid fibrin sealant that does not include any animal-derived components. The product, called Crosseal, is approved by the FDA as an adjunct to haemostasis in liver surgery. It requires no reconstitution and can be prepared for use in less than a minute, says the Brussels, Belgium-based firm. The sealant is being sold in the US by the American Red Cross Plasma Services, which formed a long-term marketing and distribution deal with Omrix earlier this year. Omrix markets a similar product, Quixil, in Europe, Latin America and Israel.